keyword
MENU ▼
Read by QxMD icon Read
search

Chemotherapeutic agent induced cardiomyopathy

keyword
https://www.readbyqxmd.com/read/27926539/chemotherapy-related-cardiac-dysfunction-grey-area-in-type-i-and-type-ii-classification
#1
Rohit Moudgil, Haissam Haddad
PURPOSE OF REVIEW: The main aim of this review is to address and challenge an old nomenclature of reversible versus irreversible chemotherapy-induced cardiomyopathy. RECENT FINDINGS: Chemotherapy-related cardiac dysfunction (CRCD) has been often characterized as type I or type II. Type I CRCD (e.g., anthracycline) represents a group of chemotherapeutic agents that has often been correlated with irreversible cardiac dysfunction. Conversely, type II CRCD (e.g., trastuzumab) represents a group of anticancer agents that has been considered as reversible...
December 6, 2016: Current Opinion in Cardiology
https://www.readbyqxmd.com/read/27755245/novel-insights-in-pathophysiology-of-antiblastic-drugs-induced-cardiotoxicity-and-cardioprotection
#2
Martino Deidda, Rosalinda Madonna, Ruggiero Mango, Pasquale Pagliaro, Pier P Bassareo, Lucia Cugusi, Silvio Romano, Maria Penco, Francesco Romeo, Giuseppe Mercuro
Despite advances in supportive and protective therapy for myocardial function, heart failure caused by various clinical conditions, including cardiomyopathy due to antineoplastic therapy, remains a major cause of morbidity and mortality. Because of the limitations associated with current therapies, investigators have been searching for alternative treatments that can effectively repair the damaged heart and permanently restore its function. Damage to the heart can result from both traditional chemotherapeutic agents, such as anthracyclines, and new targeted therapies, such as trastuzumab...
May 2016: Journal of Cardiovascular Medicine
https://www.readbyqxmd.com/read/27609196/validating-the-pharmacogenomics-of-chemotherapy-induced-cardiotoxicity-what-is-missing
#3
REVIEW
Tarek Magdy, Brian T Burmeister, Paul W Burridge
The cardiotoxicity of certain chemotherapeutic agents is now well-established, and has led to the development of the field of cardio-oncology, increased cardiac screening of cancer patients, and limitation of patients' maximum cumulative chemotherapeutic dose. The effect of chemotherapeutic regimes on the heart largely involves cardiomyocyte death, leading to cardiomyopathy and heart failure, or the induction of arrhythmias. Of these cardiotoxic drugs, those resulting in clinical cardiotoxicity can range from 8 to 26% for doxorubicin, 7-28% for trastuzumab, or 5-30% for paclitaxel...
December 2016: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27461436/echocardiography-and-alternative-cardiac-imaging-strategies-for-long-term-cardiotoxicity-surveillance-of-cancer-survivors-treated-with-chemotherapy-and-or-radiation-exposure
#4
REVIEW
Vinisha Garg, Gabriel Vorobiof
Cardiotoxicity from chemotherapy is a leading cause of morbidity and mortality in cancer survivors. Cardiotoxic effects include left ventricular systolic dysfunction, coronary artery disease, hypertension, bradycardia, arrhythmias, pericardial disease, valvular disease, and radiation-induced restrictive cardiomyopathy. Noninvasive cardiac imaging has been at the forefront of detecting cardiotoxicity in patients receiving chemotherapeutic agents known to adversely affect cardiac structure and function. Regimens for cardiotoxicity surveillance prior to and during chemotherapy administration have been proposed; however, optimal screening for and treatment of long-term cancer survivors have yet to be clarified...
August 2016: Current Oncology Reports
https://www.readbyqxmd.com/read/27294099/sarco-mir-friend-or-foe-a-perspective-on-the-mechanisms-of-doxorubicin-induced-cardiomyopathy
#5
Louis A Saddic, Jochen D Muehlschlegel
Anthracyclines are a class of chemotherapeutics used to treat a variety of human cancers including both solid tumors such as breast, ovarian, and lung, as well as malignancies of the blood including leukemia and lymphoma. Despite being extremely effective anti-cancer agents, the application of these drugs is offset by side effects, most notably cardiotoxicity. Many patients treated with doxorubicin (DOX), one of the most common anthracyclines used in oncology, will develop radiographic signs and/or symptoms of cardiomyopathy...
May 2016: Annals of Translational Medicine
https://www.readbyqxmd.com/read/27183528/novel-insights-in-pathophysiology-of-antiblastic-drugs-induced-cardiotoxicity-and-cardioprotection
#6
Martino Deidda, Rosalinda Madonna, Ruggiero Mango, Pasquale Pagliaro, Pier P Bassareo, Lucia Cugusi, Silvio Romano, Maria Penco, Francesco Romeo, Giuseppe Mercuro
Despite advances in supportive and protective therapy for myocardial function, heart failure caused by various clinical conditions, including cardiomyopathy due to antineoplastic therapy, remains a major cause of morbidity and mortality. Because of the limitations associated with current therapies, investigators have been searching for alternative treatments that can effectively repair the damaged heart and permanently restore its function. Damage to the heart can result from both traditional chemotherapeutic agents, such as anthracyclines, and new targeted therapies, such as trastuzumab...
May 2016: Journal of Cardiovascular Medicine
https://www.readbyqxmd.com/read/27167338/matricellular-protein-ccn1-mediates-doxorubicin-induced-cardiomyopathy-in-mice
#7
Pei-Ling Hsu, Fan-E Mo
Doxorubicin (DOX) is an effective chemotherapeutic agent however its clinical use is limited by its cumulative cardiotoxicity. Matricellular protein CCN1 mediates work-overload-induced cardiac injury. We aimed to assess the role of CCN1 in DOX-associated cardiomyopathy. Here we discovered CCN1 expression in the myocardium 1 day after DOX treatment (15 mg/kg; i.p.) in mice. Whereas CCN1 synergizes with Fas ligand (FasL) to induce cardiomyocyte apoptosis, we found that FasL was also induced by DOX in the heart...
June 14, 2016: Oncotarget
https://www.readbyqxmd.com/read/26897275/cardiomyopathy-associated-with-targeted-therapy-for-breast-cancer
#8
REVIEW
Kamesh Sivagnanam, Zia U Rahman, Timir Paul
BACKGROUND: Chemotherapeutic agents directed against human epidermal growth factor receptor 2 (HER-2) have significantly improved the prognosis of patients who are positive for this receptor. However, cardiomyopathy remains as a common adverse effect of using these agents. MATERIALS AND METHODS: Literature search was conducted via PubMed using the keywords of "Trastuzumab Cardiomyopathy," "Lapatinib Cardiomyopathy" and "Pertuzumab Cardiomyopathy," which provided 104 results...
February 2016: American Journal of the Medical Sciences
https://www.readbyqxmd.com/read/26491536/chemotherapy-induced-cardiotoxicity-overview-of-the-roles-of-oxidative-stress
#9
REVIEW
Paweorn Angsutararux, Sudjit Luanpitpong, Surapol Issaragrisil
Chemotherapy-induced cardiotoxicity is a serious complication that poses a serious threat to life and limits the clinical use of various chemotherapeutic agents, particularly the anthracyclines. Understanding molecular mechanisms of chemotherapy-induced cardiotoxicity is a key to effective preventive strategies and improved chemotherapy regimen. Although no reliable and effective preventive treatment has become available, numerous evidence demonstrates that chemotherapy-induced cardiotoxicity involves the generation of reactive oxygen species (ROS)...
2015: Oxidative Medicine and Cellular Longevity
https://www.readbyqxmd.com/read/26471226/ameliorative-effect-of-naringin-against-doxorubicin-induced-acute-cardiac-toxicity-in-rats
#10
Mohit Kwatra, Vikas Kumar, Ashok Jangra, Murli Mishra, Sahabuddin Ahmed, Pinaki Ghosh, Divya Vohora, Razia Khanam
CONTEXT: Doxorubicin (Dox) is one of the most active chemotherapeutic agents used to treat various types of cancers. Its clinical utility is compromised due to fatal cardiac toxicity characterized by an irreversible cardiomyopathy. OBJECTIVE: This study evaluates the cardioprotective potential of naringin (NR) against Dox-induced acute cardiac toxicity in rats. MATERIALS AND METHODS: Male Wistar rats were randomly divided into five groups...
2016: Pharmaceutical Biology
https://www.readbyqxmd.com/read/26455245/ventricular-assist-devices-in-patients-with-chemotherapy-induced-cardiomyopathy-new-modalities
#11
Omer Ali Sayin, Cenk Ozpeker, Michael Schoenbrodt, Fahrettin Oz, Jochen Borgermann, Jan Gummert, Michiel Morshuis
INTRODUCTION: Cardiotoxicity is a fatal complication of chemotherapeutic agents in which the implantation of a mechanical circulatory support system (MCS) can be a life-saving modality. The aim of this article is to analyse this available therapeutic option for patients with cardiotoxicity induced by treatment of malignancy in the light of current literature. We analysed our recent experience with MCS implantations in patients who have advanced heart failure associated with chemotherapy-induced cardiotoxicity...
August 2015: Acta Cardiologica
https://www.readbyqxmd.com/read/26399268/cardioprotective-role-of-%C3%AE-blockers-and-angiotensin-antagonists-in-early-onset-anthracyclines-induced-cardiotoxicity-in-adult-patients-a-systematic-review-and-meta-analysis
#12
REVIEW
Seongseok Yun, Nicole D Vincelette, Ivo Abraham
BACKGROUND: Anthracyclines are commonly used chemotherapeutic agents with proven efficacy in such malignancies as breast cancer, Hodgkin and non-Hodgkin lymphomas. These agents are associated with irreversible accumulative dose-related cardiomyopathy. Many agents have been examined to reduce cardiotoxicity risk. AIMS: We performed a systematic review and meta-analysis to determine the efficacy of β-blockers and angiotensin antagonists to prevent early-onset anthracyclines-induced left ventricular dysfunction and cardiac events...
November 2015: Postgraduate Medical Journal
https://www.readbyqxmd.com/read/26338137/chemotherapy-induced-cardiomyopathy
#13
REVIEW
Angela Y Higgins, Thomas D O'Halloran, James D Chang
Cardiomyopathy is an adverse outcome of antineoplastic drug therapy that has become increasingly relevant in the management of cancer survivors. As the efficacy of anticancer treatments has improved, long-term outcomes are altered by the development of cardiotoxicity, which may be associated with an even worse prognosis than that of the underlying malignancy. From the research into mechanisms, prevention, and treatment, the specialized field of cardio-oncology has evolved, but the recognition and appropriate management of these patients is important for the general internist and general cardiologist as well...
November 2015: Heart Failure Reviews
https://www.readbyqxmd.com/read/26300915/multimodality-imaging-in-cardiooncology
#14
REVIEW
Fausto Pizzino, Giampiero Vizzari, Rubina Qamar, Charles Bomzer, Scipione Carerj, Concetta Zito, Bijoy K Khandheria
Cardiotoxicity represents a rising problem influencing prognosis and quality of life of chemotherapy-treated patients. Anthracyclines and trastuzumab are the drugs most commonly associated with development of a cardiotoxic effect. Heart failure, myocardial ischemia, hypertension, myocarditis, and thrombosis are typical manifestation of cardiotoxicity by chemotherapeutic agents. Diagnosis and monitoring of cardiac side-effects of cancer treatment is of paramount importance. Echocardiography and nuclear medicine methods are widely used in clinical practice and left ventricular ejection fraction is the most important parameter to asses myocardial damage secondary to chemotherapy...
2015: Journal of Oncology
https://www.readbyqxmd.com/read/25688890/risk-assessment-and-management-of-anthracycline-and-her2-receptor-inhibitor-induced-cardiomyopathy
#15
REVIEW
Eiman Jahangir, Sangeeta Shah, Kelly Shum, Caitlin Baxter, Jill D Fitzpatrick, John Cole, Yvonne Gilliland, Nichole M Polin
With the advent and increased use of chemotherapeutic agents and radiation therapy, cancer survival rates have increased. With increased survival, both acute and chronic cardiotoxic adverse effects have emerged. The growing need for managing the treatment of individuals with chemotherapy-induced cardiotoxicity has led to the formation of cardio-oncology programs throughout the United States. These programs concentrate on many aspects of cardiac disease in the oncology patient. Of these, the cardiotoxic effects (particularly cardiomyopathy) of anthracyclines and HER2 receptor inhibitors are a large focus of cardio-oncology practice...
February 2015: Southern Medical Journal
https://www.readbyqxmd.com/read/25687365/advanced-heart-failure-due-to-cancer-therapy
#16
REVIEW
Sachin Shah, Anju Nohria
Certain chemotherapeutic agents and mediastinal irradiation can be cardiotoxic and place cancer survivors at risk for developing advanced heart failure (HF). Anthracyclines are the prototypical agents associated with left ventricular (LV) dysfunction. Newer agents including trastuzumab and certain tyrosine kinase inhibitors such as sunitinib can also cause cardiomyopathy. Cancer survivors with advanced HF refractory to standard medical management should be considered for advanced therapies, including mechanical circulatory support (MCS) and transplantation...
2015: Current Cardiology Reports
https://www.readbyqxmd.com/read/25569804/cannabidiol-protects-against-doxorubicin-induced-cardiomyopathy-by-modulating-mitochondrial-function-and-biogenesis
#17
Enkui Hao, Partha Mukhopadhyay, Zongxian Cao, Katalin Erdélyi, Eileen Holovac, Lucas Liaudet, Wen-Shin Lee, György Haskó, Raphael Mechoulam, Pál Pacher
Doxorubicin (DOX) is a widely used, potent chemotherapeutic agent; however, its clinical application is limited because of its dose-dependent cardiotoxicity. DOX's cardiotoxicity involves increased oxidative/nitrative stress, impaired mitochondrial function in cardiomyocytes/endothelial cells and cell death. Cannabidiol (CBD) is a nonpsychotropic constituent of marijuana, which is well tolerated in humans, with antioxidant, antiinflammatory and recently discovered antitumor properties. We aimed to explore the effects of CBD in a well-established mouse model of DOX-induced cardiomyopathy...
2015: Molecular Medicine
https://www.readbyqxmd.com/read/25549075/capecitabine-induced-takotsubo-cardiomyopathy-a-case-report-and-literature-review
#18
Abdulraheem Qasem, Aref A Bin Abdulhak, Abdelrahman Aly, Jill Moormeier
Capecitabine is an orally administered chemotherapeutic agent that is metabolized at the tumor site to 5-fluorouracil and thought to be without significant cardiac toxicity. We report a rare case of takotsubo cardiomyopathy that is thought to be related to capecitabine where the patient presented with chest pain, and ST elevation within 48 hours of capecitabine therapy. Workup included cardiac catheterization and coronary angiogram that showed nonobstructive coronary artery disease and anteroapical left ventricular wall motion abnormality with left ventricular ejection fraction of 35%...
September 2016: American Journal of Therapeutics
https://www.readbyqxmd.com/read/25529476/identification-of-novel-biomarkers-for-doxorubicin-induced-toxicity-in-human-cardiomyocytes-derived-from-pluripotent-stem-cells
#19
Gustav Holmgren, Jane Synnergren, Yalda Bogestål, Caroline Améen, Karolina Åkesson, Sandra Holmgren, Anders Lindahl, Peter Sartipy
Doxorubicin is a chemotherapeutic agent indicated for the treatment of a variety of cancer types, including leukaemia, lymphomas, and many solid tumours. The use of doxorubicin is, however, associated with severe cardiotoxicity, often resulting in early discontinuation of the treatment. Importantly, the toxic symptoms can occur several years after the termination of the doxorubicin administration. In this study, the toxic effects of doxorubicin exposure have been investigated in cardiomyocytes derived from human embryonic stem cells (hESC)...
February 3, 2015: Toxicology
https://www.readbyqxmd.com/read/25504881/visnagin-protects-against-doxorubicin-induced-cardiomyopathy-through-modulation-of-mitochondrial-malate-dehydrogenase
#20
Yan Liu, Aarti Asnani, Lin Zou, Victoria L Bentley, Min Yu, You Wang, Graham Dellaire, Kumar S Sarkar, Matthew Dai, Howard H Chen, David E Sosnovik, Jordan T Shin, Daniel A Haber, Jason N Berman, Wei Chao, Randall T Peterson
Doxorubicin is a highly effective anticancer chemotherapy agent, but its use is limited by its cardiotoxicity. To develop a drug that prevents this toxicity, we established a doxorubicin-induced cardiomyopathy model in zebrafish that recapitulates the cardiomyocyte apoptosis and contractility decline observed in patients. Using this model, we screened 3000 compounds and found that visnagin (VIS) and diphenylurea (DPU) rescue the cardiac performance and circulatory defects caused by doxorubicin in zebrafish...
December 10, 2014: Science Translational Medicine
keyword
keyword
82652
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"